BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients.
“The Lundquist Institute is renowned for its scientific research
and drug discoveries, and we look forward to developing a close
relationship with their talented scientists in the hope of
translating their discoveries into medicines with meaningful
benefit for patients,” said BridgeBio CEO and Founder Neil
Kumar, Ph.D.
Under the established two-year
partnership, BridgeBio will work closely with The Lundquist
Institute researchers to identify programs that may have the
potential to become therapies for patients with genetically
driven conditions and cancers. BridgeBio will potentially
sponsor research programs and support the development of
Lundquist programs and clinical investigations through its
licensing and affiliate development model.
“By coupling our world-class scientific discoveries with the resources and well-seasoned team at BridgeBio, we have the opportunity to create advancements in therapeutics for genetic diseases,” said Rubayath Mohsen, M.S., Manager of Business Development and Technology Transfer from The Lundquist Institute. “Based on their track record in working closely with researchers, we are optimistic about developing our technologies with BridgeBio and look forward to seeing what we can do together to develop new therapeutics for patients in need.”
BridgeBio partners with top academic and research institutions throughout the U.S., including The Lundquist Institute, to support early, promising research in genetically driven diseases and cancers with clear genetic drivers. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.
With trust, respect and science at the forefront of all collaborations, BridgeBio will continue developing similar long-term partnerships to support its mission of pioneering critical medicines for patients with certain cancers and genetically driven conditions as quickly and safely as possible.
About The Lundquist Institute: “Research with
Reach”™
The Lundquist Institute is an engine of innovation with a
global reach and a 69-year reputation of improving and saving
lives. With its new medical research building, its
state-of-the-art incubator, “BioLabs at The Lundquist,” existing
laboratory and support infrastructure, and a 15-acre tech park
in the planning stages, the Lundquist Institute serves as a hub
for the Los Angeles area’s burgeoning biotech scene. The
research institute has over 100 principal investigators (PhDs,
MDs, and MD/PhDs) working on more than 600 research studies,
including therapies for numerous, and often fatal orphan
diseases. Find out more at https://lundquist.org.
About BridgeBio Pharma:
BridgeBio is a
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer
from genetic diseases and cancers with clear genetic drivers.
BridgeBio’s pipeline of over 30 development programs ranges from
early science to advanced clinical trials and its commercial
organization is focused on delivering the company’s first
approved therapy. BridgeBio was founded in 2015 and its team of
experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help
patients as quickly as possible. For more information visit bridgebiodev.wpengine.com.
BridgeBio Pharma Forward-Looking Statements
This press release contains forward-looking statements.
Statements we make in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend
these forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act and Section 21E of the
Exchange Act and are making this statement for purposes of
complying with those safe harbor provisions. These
forward-looking statements, including statements relating to
expectations, plans, and prospects regarding our ability to
build on The Lundquist Institute’s scientific innovation and
genetic disease research and translate them into meaningful
medicines for patients in need, the success of current and
future relationships with third-party collaborators and academic
partners, and the potential ability of our product candidates to
treat genetically driven diseases and cancers with clear genetic
drivers, reflect our current views about our plans, intentions,
expectations, strategies and prospects, and are based on the
information currently available to us and on assumptions we have
made and are not forecasts, promises nor guarantees. Although we
believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by these forward-looking
statements are reasonable, we can give no assurance that the
plans, intentions, expectations or strategies will be attained
or achieved. Furthermore, actual results may differ materially
from those described in the forward-looking statements and will
be affected by a number of risks, uncertainties and assumptions,
including, but not limited to, the success of our product
candidates to treat genetically driven diseases and cancers with
clear genetic drivers, the success of our collaboration with The
Lundquist Institute, as well as those risks set forth in the
Risk Factors section of BridgeBio Pharma’s most recent Annual
Report on Form 10-K and BridgeBio Pharma’s other SEC filings.
Moreover, we operate in a very competitive and rapidly changing
environment in which new risks emerge from time to time. Except
as required by applicable law, we assume no obligation to update
publicly any forward-looking statements, whether as a result of
new information, future events or otherwise.
The Lundquist Institute Contact:
Max
Benavidez
The Lundquist Institute
[email protected]
(310) 200-2682
BridgeBio Contact:
Grace Rauh
BridgeBio
Pharma, Inc.
[email protected]
(917) 232-5478